Impact of the Voltage-Gated Calcium Channel Antagonist Nimodipine on the Development of Oligodendrocyte Precursor Cells
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043716 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Michael Enders und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Neuroanatomy, Medical Faculty, University of Bonn, 53115 Bonn, Germany. Hauptthemen laut MEDLINE: Oligodendrocyte Precursor Cells, Encephalomyelitis, Autoimmune, Experimental, Multiple Sclerosis, MicroRNAs. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, DFG IRTG2168.
Abstract (Originalsprache)
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). While most of the current treatment strategies focus on immune cell regulation, except for the drug siponimod, there is no therapeutic intervention that primarily aims at neuroprotection and remyelination. Recently, nimodipine showed a beneficial and remyelinating effect in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. Nimodipine also positively affected astrocytes, neurons, and mature oligodendrocytes. Here we investigated the effects of nimodipine, an L-type voltage-gated calcium channel antagonist, on the expression profile of myelin genes and proteins in the oligodendrocyte precursor cell (OPC) line Oli-Neu and in primary OPCs. Our data indicate that nimodipine does not have any effect on myelin-related gene and protein expression. Furthermore, nimodipine treatment did not result in any morphological changes in these cells. However, RNA sequencing and bioinformatic analyses identified potential micro (mi)RNA that could support myelination after nimodipine treatment compared to a dimethyl sulfoxide (DMSO) control. Additionally, we treated zebrafish with nimodipine and observed a significant increase in the number of mature oligodendrocytes (* p≤ 0.05). Taken together, nimodipine seems to have different positive effects on OPCs and mature oligodendrocytes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Neuroanatomy, Medical Faculty, University of Bonn, 53115 Bonn, Germany.
- Institute of Anatomy and Cell Biology, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
- Department of Biology, Animal Physiology, University of Erlangen-Nuremberg, 91058 Erlangen, Germany.
- Institute of Human Genetics, University Hospital Erlangen, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
- Institute of Anatomy and Cell Biology, Medical Faculty, University of Bonn, 53115 Bonn, Germany.
ORCID-Profile: Alicia Weier, Young An, Franziska Bremm, Stefanie Kuerten
Förderung
- Deutsche Forschungsgemeinschaft
- DFG IRTG2168
Zitieren
APA
Enders, M., Weier, A., Chunder, R., An, Y., Bremm, F., Feigenspan, A., Buettner, C., Ekici, A. B., Mingardo, E., Odermatt, B., & Kuerten, S. (2023). Impact of the Voltage-Gated Calcium Channel Antagonist Nimodipine on the Development of Oligodendrocyte Precursor Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043716
Vancouver
Enders M, Weier A, Chunder R, An Y, Bremm F, Feigenspan A, et al. Impact of the Voltage-Gated Calcium Channel Antagonist Nimodipine on the Development of Oligodendrocyte Precursor Cells. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043716
BibTeX
@article{Enders2023,
author = {Enders, Michael and Weier, Alicia and Chunder, Rittika and An, Young and Bremm, Franziska and Feigenspan, Andreas and Buettner, Christian and Ekici, Arif Bülent and Mingardo, Enrico and Odermatt, Benjamin and Kuerten, Stefanie},
title = {Impact of the Voltage-Gated Calcium Channel Antagonist Nimodipine on the Development of Oligodendrocyte Precursor Cells},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043716}
}
EUVIMED